Traws Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Traws Pharma, Inc. (TRAW) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.38 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.38, a 63.10% decline year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $3.74.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.64, a 59.49% decline year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.58.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.21, a 69.97% decline from fiscal 2024.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.36, a 65.36% decline from fiscal 2023.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $21.25, a 1685.71% increase from fiscal 2022.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.19, a 74.13% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.38 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | $1.38 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | $2.21 10-K · filed 2026-04-15 | |||||
| 2025-09-30 | $2.34 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | $2.34 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | $3.74 10-Q · filed 2026-05-15 | |||||
| 2024-12-31 | $7.36 10-K · filed 2026-04-15 | |||||
| 2024-09-30 | $7.49 10-Q · filed 2025-11-13 | |||||
| 2023-12-31 | $21.25 10-K · filed 2025-03-31 | $0.85 10-K · filed 2024-04-01 | ||||
| 2023-09-30 | $17.79 10-Q · filed 2024-11-14 | $0.77 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $0.64 10-Q · filed 2024-08-15 | |||||
| 2023-03-31 | $0.64 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $1.19 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | $1.32 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $1.51 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | $1.58 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | $4.60 10-K · filed 2023-03-30 | |||||
| 2020-12-31 | $0.25 10-K · filed 2021-03-18 | |||||
| 2019-12-31 | $0.44 10-K · filed 2021-03-18 | |||||
| 2018-12-31 | $1.18 10-K · filed 2020-03-27 | |||||
| 2017-12-31 | $1.76 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |